Efficacy of dietary supplement with nutraceutical composed combined with extremely-low-frequency electromagnetic fields in carpal tunnel syndrome
[Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group...
Saved in:
| Published in | Journal of Physical Therapy Science Vol. 30; no. 6; pp. 777 - 784 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Society of Physical Therapy Science
01.01.2018
Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0915-5287 2187-5626 |
| DOI | 10.1589/jpts.30.777 |
Cover
| Abstract | [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical + extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo + extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical was twice daily for one month in the 1-A group and both groups received extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2). [Results] At T1 and T2 were not significant differences in outcome measures between the two groups. In group 1-A a significant improvement in the scales were observed at T1 and T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A they were maintained at 3 months post-treatment. |
|---|---|
| AbstractList | [Purpose] The aim of this study was to investigate the clinical effects of a
nutraceutical composed (Xinepa
®
) combined with extremely-low-frequency
electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one
patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical
+ extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo +
extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical
was twice daily for one month in the 1-A group and both groups received
extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times
per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale
and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at
pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2).
[Results] At T1 and T2 were not significant differences in outcome measures between the
two groups. In group 1-A a significant improvement in the scales were observed at T1 and
T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects
from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A
they were maintained at 3 months post-treatment. [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa ) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical + extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo + extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical was twice daily for one month in the 1-A group and both groups received extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2). [Results] At T1 and T2 were not significant differences in outcome measures between the two groups. In group 1-A a significant improvement in the scales were observed at T1 and T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A they were maintained at 3 months post-treatment. [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical + extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo + extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical was twice daily for one month in the 1-A group and both groups received extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2). [Results] At T1 and T2 were not significant differences in outcome measures between the two groups. In group 1-A a significant improvement in the scales were observed at T1 and T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A they were maintained at 3 months post-treatment. [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical + extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo + extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical was twice daily for one month in the 1-A group and both groups received extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2). [Results] At T1 and T2 were not significant differences in outcome measures between the two groups. In group 1-A a significant improvement in the scales were observed at T1 and T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A they were maintained at 3 months post-treatment.[Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency electromagnetic fields in the carpal tunnel syndrome. [Subjects and Methods] Thirty-one patients with carpal tunnel syndrome were randomized into group 1-A (N=16) (nutraceutical + extremely-low-frequency electromagnetic fields) and group 2-C (n=15) (placebo + extremely-low-frequency electromagnetic fields). The dietary supplement with nutraceutical was twice daily for one month in the 1-A group and both groups received extremely-low-frequency electromagnetic fields at the level of the carpal tunnel 3 times per week for 12 sessions. The Visual Analogue Scale for pain, the Symptoms Severity Scale and Functional Severity Scale of the Boston Carpal Tunnel Questionnaire were used at pre-treatment (T0), after the end of treatment (T1) and at 3 months post-treatment (T2). [Results] At T1 and T2 were not significant differences in outcome measures between the two groups. In group 1-A a significant improvement in the scales were observed at T1 and T2. In group 2-C it was observed only at T1. [Conclusion] Significant clinical effects from pre-treatment to the end of treatment were shown in both groups. Only in group 1-A they were maintained at 3 months post-treatment. |
| Author | Piccinini, Giulia Paolucci, Teresa Marsilli, Gabriella Nusca, Sveva Maria Torre, Giuseppe La Vulpiani, Maria Chiara Saraceni, Vincenzo Maria Mannocci, Alice Villani, Ciro |
| Author_xml | – sequence: 1 fullname: Saraceni, Vincenzo Maria organization: Complex Unit of Physical Medicine and Rehabilitation, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Italy – sequence: 1 fullname: Marsilli, Gabriella organization: Unit of Physical Medicine and Rehabilitation, Sant’Andrea Hospital, “Sapienza” University of Rome: Via di Grottarossa 1035/1039, 00189, Rome, Italy – sequence: 1 fullname: Torre, Giuseppe La organization: Department of Public Health and Infectious Diseases, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Italy – sequence: 1 fullname: Vulpiani, Maria Chiara organization: Unit of Physical Medicine and Rehabilitation, Sant’Andrea Hospital, “Sapienza” University of Rome: Via di Grottarossa 1035/1039, 00189, Rome, Italy – sequence: 1 fullname: Villani, Ciro organization: University Department of Anatomic, Histologic, Forensic and Locomotor Apparatus Sciences, Section of Locomotor Apparatus Sciences, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Italy – sequence: 1 fullname: Piccinini, Giulia organization: Unit of Physical Medicine and Rehabilitation, Sant’Andrea Hospital, “Sapienza” University of Rome: Via di Grottarossa 1035/1039, 00189, Rome, Italy – sequence: 1 fullname: Paolucci, Teresa organization: Complex Unit of Physical Medicine and Rehabilitation, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Italy – sequence: 1 fullname: Nusca, Sveva Maria organization: Unit of Physical Medicine and Rehabilitation, Sant’Andrea Hospital, “Sapienza” University of Rome: Via di Grottarossa 1035/1039, 00189, Rome, Italy – sequence: 1 fullname: Mannocci, Alice organization: Department of Public Health and Infectious Diseases, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29950763$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk2LFDEQhoOsuLOrJ-_S4EWQHvPRSXdfBFlWV1jwoueQTqpnMqSTNkm7zs_wH5vZWQdd8JJUyFMv9VbVBTrzwQNCLwleE97173ZzTmuG123bPkErSrq25oKKM7TCPeE1p117ji5S2mFMW9x0z9A57XuOW8FW6Nf1OFqt9L4KY2UsZBX3VVrm2cEEPld3Nm8rv-SoNCy5kK7SYZpDAnMIButLcA_BzxxLjtvXLtzVY4TvC_iiCw50jmFSGw9FoBotOJMq6yut4lz08uI9uCrtvSkYPEdPR-USvHi4L9G3j9dfr27q2y-fPl99uK11g_u2Hg3BhLdqaHoYaNM3vIFBsI6ZZgA2YAPcsE5xbQSFZjC4FyMdDOGqI5iKll2i90fdeRkmMLq4jcrJOdqp9EAGZeW_P95u5Sb8kAITURpYBN48CMRQvKYsJ5s0OKc8hCVJigVpMG9aUtDXj9BdWKIv9iSljArMOGaFevV3RadS_kyrAG-PgI4hpQjjCSFYHnZBHnZBMizLLhSaPKK1zSrbcLBj3X9ybo45u5TVBk76KpbROTix4nDcPygmncSEnRC9VVGCZ78B0NXXUw |
| CitedBy_id | crossref_primary_10_4236_mps_2022_122002 crossref_primary_10_1016_j_jnrt_2024_100116 crossref_primary_10_17392_1679_23 crossref_primary_10_1007_s42235_021_0015_1 |
| Cites_doi | 10.1054/jhsb.2002.0762 10.1016/j.apmr.2010.02.013 10.1371/journal.pone.0104973 10.1310/CH1N-YBNU-G3CU-JBXR 10.3109/15368378.2010.482487 10.1002/mus.880161220 10.1136/ard.38.6.560 10.1111/j.1526-4637.2007.00324.x 10.1016/j.berh.2015.04.026 10.1186/s13063-016-1324-2 10.1186/1741-7015-8-18 10.1002/anie.201107724 10.2165/00126839-200203040-00001 10.1136/bmjopen-2016-012053 10.1177/0394632015584501 10.1177/030089160509100206 10.1186/1471-2474-7-78 10.1177/197140090702000612 10.1523/JNEUROSCI.5803-08.2009 10.3344/kjp.2012.25.3.202 10.4103/2277-9175.186983 10.3390/molecules16064567 10.1002/mus.10185 10.3233/BMR-2000-152-305 10.1097/00043764-199710000-00007 10.1023/A:1025184912494 10.4103/0250-474X.65012 10.1142/S0218810414500087 10.4103/1673-5374.187063 10.1371/journal.pone.0147051 10.1002/14651858.CD004573.pub3 10.1155/2014/891310 10.1053/meta.2001.24914 10.1212/WNL.43.11.2406 10.1136/bmj.1.5186.1611 10.1186/1471-2296-11-54 |
| ContentType | Journal Article |
| Copyright | 2018 by the Society of Physical Therapy Science. Published by IPEC Inc. Copyright Japan Science and Technology Agency 2018 2018©by the Society of Physical Therapy Science. Published by IPEC Inc. 2018 |
| Copyright_xml | – notice: 2018 by the Society of Physical Therapy Science. Published by IPEC Inc. – notice: Copyright Japan Science and Technology Agency 2018 – notice: 2018©by the Society of Physical Therapy Science. Published by IPEC Inc. 2018 |
| DBID | AAYXX CITATION NPM 7TS NAPCQ 7X8 5PM |
| DOI | 10.1589/jpts.30.777 |
| DatabaseName | CrossRef PubMed Physical Education Index Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Nursing & Allied Health Premium Physical Education Index MEDLINE - Academic |
| DatabaseTitleList | PubMed Nursing & Allied Health Premium MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Physical Therapy |
| EISSN | 2187-5626 |
| EndPage | 784 |
| ExternalDocumentID | PMC6016299 29950763 10_1589_jpts_30_777 article_jpts_30_6_30_jpts_2018_013_article_char_en |
| Genre | Journal Article |
| GroupedDBID | .55 07C 29L 2WC 53G 5GY AAEJM AAWTL ACGFO ADBBV ADRAZ AENEX AIAGR AJJEV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BKOMP BMSDO CS3 DIK DU5 E3Z EBS EJD FRP GX1 HYE JMI JSF JSH KQ8 M48 MOJWN OK1 OVT P2P PGMZT RJT RNS RPM RZJ TKC TR2 W2D X7M XSB AAYXX CITATION ACRZS NPM 7TS NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c4097-fd10157ab49eb249454eb6383d4be3b0de5d38a5cd62e4bd096f2bd15a8102673 |
| IEDL.DBID | M48 |
| ISSN | 0915-5287 |
| IngestDate | Thu Aug 21 18:24:14 EDT 2025 Fri Jul 11 06:48:53 EDT 2025 Mon Jun 30 05:41:48 EDT 2025 Fri Mar 21 18:55:43 EDT 2025 Thu Apr 24 22:51:07 EDT 2025 Tue Jul 01 04:12:15 EDT 2025 Wed Sep 03 06:20:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Magnetic fields Carpal tunnel syndrome Nutraceuticals |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4097-fd10157ab49eb249454eb6383d4be3b0de5d38a5cd62e4bd096f2bd15a8102673 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1589/jpts.30.777 |
| PMID | 29950763 |
| PQID | 2232603503 |
| PQPubID | 2048495 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6016299 proquest_miscellaneous_2061405471 proquest_journals_2232603503 pubmed_primary_29950763 crossref_primary_10_1589_jpts_30_777 crossref_citationtrail_10_1589_jpts_30_777 jstage_primary_article_jpts_30_6_30_jpts_2018_013_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20180101 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 20180101 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Journal of Physical Therapy Science |
| PublicationTitleAlternate | Journal of Physical Therapy Science |
| PublicationYear | 2018 |
| Publisher | The Society of Physical Therapy Science Japan Science and Technology Agency |
| Publisher_xml | – name: The Society of Physical Therapy Science – name: Japan Science and Technology Agency |
| References | 13) Mild KH, Mattsson MO: ELF noise fields: a review. Electromagn Biol Med, 2010, 29: 72–97. 7) Crow RS: Treatment of the carpal-tunnel syndrome. BMJ, 1960, 1: 1611–1615. 31) Schulz KF, Altman DG, Moher D, CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med, 2010, 8: 18. 35) Peters-Veluthamaningal C, Winters JC, Groenier KH, et al.: Randomised controlled trial of local corticosteroid injections for carpal tunnel syndrome in general practice. BMC Fam Pract, 2010, 11: 54. 8) Chen Y, Zhao CQ, Ye G, et al.: Low-power laser therapy for carpal tunnel syndrome: effective optical power. Neural Regen Res, 2016, 11: 1180–1184. 28) Curran MW, Olson J, Morhart M, et al.: Acetyl-L-carnitine (ALCAR) to enhance nerve regeneration in carpal tunnel syndrome: study protocol for a randomized, placebo-controlled trial. Trials, 2016, 17: 200. 4) Aboonq MS: Pathophysiology of carpal tunnel syndrome. Neurosci Riyadh, 2015, 20: 4–9. 16) Notarnicola A, Maccagnano G, Tafuri S, et al.: Comparison of shock wave therapy and nutraceutical composed of Echinacea angustifolia, alpha lipoic acid, conjugated linoleic acid and quercetin (perinerv) in patients with carpal tunnel syndrome. Int J Immunopathol Pharmacol, 2015, 28: 256–262. 26) Basnet P, Skalko-Basnet N: Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011, 16: 4567–4598. 34) Leite JC, Jerosch-Herold C, Song F: A systematic review of the psychometric properties of the Boston Carpal Tunnel Questionnaire. BMC Musculoskelet Disord, 2006, 7: 78. 15) Weintraub MI, Cole SP: Neuromagnetic treatment of pain in refractory carpal tunnel syndrome: an electrophysiological and placebo analysis. J Back Musculoskeletal Rehabil, 2000, 15: 77–81. 19) Di Geronimo G, Caccese AF, Caruso L, et al.: Treatment of carpal tunnel syndrome with alpha-lipoic acid. Eur Rev Med Pharmacol Sci, 2009, 13: 133–139. 12) Dakowicz A, Kuryliszyn-Moskal A, Kosztyła-Hojna B, et al.: Comparison of the long-term effectiveness of physiotherapy programs with low-level laser therapy and pulsed magnetic field in patients with carpal tunnel syndrome. Adv Med Sci, 2011, 56: 270–274. 30) American Association of Electrodiagnostic Medicine, American Academy of Neurology, and American Academy of Physical Medicine and Rehabilitation: Practice parameter for electrodiagnostic studies in carpal tunnel syndrome: summary statement. Muscle Nerve, 2002, 25: 918–922. 32) Scott J, Huskisson EC: Vertical or horizontal visual analogue scales. Ann Rheum Dis, 1979, 38: 560. 2) Jablecki CK, Andary MT, So YT, et al. AAEM Quality Assurance Committee: Literature review of the usefulness of nerve conduction studies and electromyography for the evaluation of patients with carpal tunnel syndrome. Muscle Nerve, 1993, 16: 1392–1414. 27) Ang CD, Alviar MJ, Dans AL, et al.: Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev, 2008, (3): CD004573. 10) Jiménez Del Barrio S, Bueno Gracia E, Hidalgo García C, et al.: Conservative treatment in patients with mild to moderate carpal tunnel syndrome: a systematic review. Neurologia, 2016, S0213-4853(16)30094–9 (in Spanish). 29) American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation: Practice parameter for carpal tunnel syndrome (summary statement). Neurology, 1993, 43: 2406–2409. 40) Maestri A, De Pasquale Ceratti A, Cundari S, et al.: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori, 2005, 91: 135–138. 24) Ford I, Cotter M. A, Cameron N. E, et al: The effects of treatment with α-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. 2001, 50: 868–875. 23) Lee WY, Orestes P, Latham J, et al.: Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway. J Neurosci, 2009, 29: 9500–9509. 36) Esatbeyoglu T, Huebbe P, Ernst IM, et al.: Curcumin–from molecule to biological function. Angew Chem Int Ed Engl, 2012, 51: 5308–5332. 42) Musaev AV, Guseinova SG, Imamverdieva SS: The use of pulsed electromagnetic fields with complex modulation in the treatment of patients with diabetic polyneuropathy. Neurosci Behav Physiol, 2003, 33: 745–752. 1) Kuo TT, Lee MR, Liao YY, et al.: Assessment of median nerve mobility by ultrasound dynamic imaging for diagnosing carpal tunnel syndrome. PLoS One, 2016, 11: e0147051. 22) Gorąca A, Huk-Kolega H, Piechota A, et al.: Lipoic acid −biological activity and therapeutic potential. Pharmacol Rep, 2011, 63: 849–858. 37) Keniston RC, Nathan PA, Leklem JE, et al.: Vitamin B6, vitamin C, and carpal tunnel syndrome. A cross-sectional study of 441 adults. J Occup Environ Med, 1997, 39: 949–959. 33) Heybeli N, Kutluhan S, Demirci S, et al.: Assessment of outcome of carpal tunnel syndrome: a comparison of electrophysiological findings and a self-administered Boston questionnaire. J Hand Surg [Br], 2002, 27: 259–264. 41) Colbert AP, Markov MS, Carlson N, et al.: Static magnetic field therapy for carpal tunnel syndrome: a feasibility study. Arch Phys Med Rehabil, 2010, 91: 1098–1104. 9) Vahdatpour B, Kiyani A, Dehghan F: Effect of extracorporeal shock wave therapy on the treatment of patients with carpal tunnel syndrome. Adv Biomed Res, 2016, 5: 120. 14) Reale M, Kamal MA, Patruno A, et al.: Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration. PLoS One, 2014, 9: e104973. 38) Herzmann C, Johnson MA, Youle M: Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials, 2005, 6: 344–350. 11) Weintraub MI, Cole SP: A randomized controlled trial of the effects of a combination of static and dynamic magnetic fields on carpal tunnel syndrome. Pain Med, 2008, 9: 493–504. 3) Newington L, Harris EC, Walker-Bone K: Carpal tunnel syndrome and work. Best Pract Res Clin Rheumatol, 2015, 29: 440–453. 18) Kapoor S: Clinical applications of alpha-lipoic acid in the management of neurological disorders besides carpal tunnel syndrome. Eur Rev Med Pharmacol Sci, 2009, 13: 401–402. 6) Lewis KJ, Ross L, Coppieters MW, et al.: Education, night splinting and exercise versus usual care on recovery and conversion to surgery for people awaiting carpal tunnel surgery: a protocol for a randomised controlled trial. BMJ Open, 2016, 6: e012053. 39) De Grandis D, Minardi C: Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D, 2002, 3: 223–231. 17) Pajardi G, Bortot P, Ponti V, et al.: Clinical usefulness of oral supplementation with alpha-lipoic acid, curcumin phytosome, and B-group vitamins in patients with carpal tunnel syndrome undergoing surgical treatment. Evid Based Complement Alternat Med, 2014, 2014: 891310. 25) Kapoor S: Curcumin and its emerging role in pain modulation and pain management. Korean J Pain, 2012, 25: 202–203. 20) Ryan-Harshman M, Aldoori W: Carpal tunnel syndrome and vitamin B6. Can Fam Physician, 2007, 53: 1161–1162. 5) Sonohata M, Tsuruta T, Mine H, et al.: Clinical characteristics of neuropathic pain in patients with carpal tunnel syndrome. Hand Surg, 2014, 19: 43–48. 43) Bistolfi F: Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis. Neuroradiol J, 2007, 20: 676–693. 21) Kulkarni SK, Dhir A: An overview of curcumin in neurological disorders. Indian J Pharm Sci, 2010, 72: 149–154. 22 23 24 25 26 (10) 2016 28 29 (6) 2016; 6 30 31 32 11 33 12 34 13 35 14 (27) 1993; 43 36 15 37 16 38 17 39 18 19 1 2 3 4 5 7 8 9 40 41 20 21 27630706 - Neural Regen Res. 2016 Jul;11(7):1180-4 22787555 - Korean J Pain. 2012 Jul;25(3):202-3 12115985 - Muscle Nerve. 2002 Jun;25(6):918-22 12074615 - J Hand Surg Br. 2002 Jun;27(3):259-64 22566109 - Angew Chem Int Ed Engl. 2012 May 29;51(22):5308-32 317239 - Ann Rheum Dis. 1979 Dec;38(6):560 19961049 - Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):401-2 27079660 - Trials. 2016 Apr 14;17:200 17054773 - BMC Musculoskelet Disord. 2006 Oct 20;7:78 20599049 - Arch Phys Med Rehabil. 2010 Jul;91(7):1098-104 15948540 - Tumori. 2005 Mar-Apr;91(2):135-8 26764488 - PLoS One. 2016 Jan 14;11(1):e0147051 19641113 - J Neurosci. 2009 Jul 29;29(30):9500-9 27563630 - Adv Biomed Res. 2016 Jul 29;5:120 20707642 - Electromagn Biol Med. 2010 Aug;29(3):72-97 17872812 - Can Fam Physician. 2007 Jul;53(7):1161-2 9343760 - J Occup Environ Med. 1997 Oct;39(10):949-59 8232399 - Muscle Nerve. 1993 Dec;16(12):1392-414 22388446 - J Back Musculoskelet Rehabil. 2000 Jan 1;15(2):77-81 24641740 - Hand Surg. 2014;19(1):43-8 24300003 - Neuroradiol J. 2007 Dec 31;20(6):676-93 20670438 - BMC Fam Pract. 2010 Jul 29;11:54 25953494 - Int J Immunopathol Pharmacol. 2015 Jun;28(2):256-62 21642934 - Molecules. 2011 Jun 03;16(6):4567-98 12455197 - Drugs R D. 2002;3(4):223-31 25630774 - Neurosciences (Riyadh). 2015 Jan;20(1):4-9 19499849 - Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):133-9 25127118 - PLoS One. 2014 Aug 15;9(8):e104973 20838516 - Indian J Pharm Sci. 2010 Mar;72(2):149-54 14635988 - Neurosci Behav Physiol. 2003 Oct;33(8):745-52 11474472 - Metabolism. 2001 Aug;50(8):868-75 18777606 - Pain Med. 2008 Jul-Aug;9(5):493-504 8232968 - Neurology. 1993 Nov;43(11):2406-9 24563654 - Evid Based Complement Alternat Med. 2014;2014:891310 27638495 - BMJ Open. 2016 Sep 16;6(9):e012053 20334633 - BMC Med. 2010 Mar 24;8:18 18646107 - Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004573 16566084 - HIV Clin Trials. 2005 Nov-Dec;6(6):344-50 26612240 - Best Pract Res Clin Rheumatol. 2015 Jun;29(3):440-53 22037175 - Adv Med Sci. 2011;56(2):270-4 13813041 - Br Med J. 1960 May 28;1(5186):1611-5 22001972 - Pharmacol Rep. 2011;63(4):849-58 |
| References_xml | – reference: 19) Di Geronimo G, Caccese AF, Caruso L, et al.: Treatment of carpal tunnel syndrome with alpha-lipoic acid. Eur Rev Med Pharmacol Sci, 2009, 13: 133–139. – reference: 23) Lee WY, Orestes P, Latham J, et al.: Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway. J Neurosci, 2009, 29: 9500–9509. – reference: 43) Bistolfi F: Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis. Neuroradiol J, 2007, 20: 676–693. – reference: 3) Newington L, Harris EC, Walker-Bone K: Carpal tunnel syndrome and work. Best Pract Res Clin Rheumatol, 2015, 29: 440–453. – reference: 6) Lewis KJ, Ross L, Coppieters MW, et al.: Education, night splinting and exercise versus usual care on recovery and conversion to surgery for people awaiting carpal tunnel surgery: a protocol for a randomised controlled trial. BMJ Open, 2016, 6: e012053. – reference: 32) Scott J, Huskisson EC: Vertical or horizontal visual analogue scales. Ann Rheum Dis, 1979, 38: 560. – reference: 14) Reale M, Kamal MA, Patruno A, et al.: Neuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegeneration. PLoS One, 2014, 9: e104973. – reference: 26) Basnet P, Skalko-Basnet N: Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011, 16: 4567–4598. – reference: 29) American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation: Practice parameter for carpal tunnel syndrome (summary statement). Neurology, 1993, 43: 2406–2409. – reference: 38) Herzmann C, Johnson MA, Youle M: Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials, 2005, 6: 344–350. – reference: 9) Vahdatpour B, Kiyani A, Dehghan F: Effect of extracorporeal shock wave therapy on the treatment of patients with carpal tunnel syndrome. Adv Biomed Res, 2016, 5: 120. – reference: 4) Aboonq MS: Pathophysiology of carpal tunnel syndrome. Neurosci Riyadh, 2015, 20: 4–9. – reference: 10) Jiménez Del Barrio S, Bueno Gracia E, Hidalgo García C, et al.: Conservative treatment in patients with mild to moderate carpal tunnel syndrome: a systematic review. Neurologia, 2016, S0213-4853(16)30094–9 (in Spanish). – reference: 33) Heybeli N, Kutluhan S, Demirci S, et al.: Assessment of outcome of carpal tunnel syndrome: a comparison of electrophysiological findings and a self-administered Boston questionnaire. J Hand Surg [Br], 2002, 27: 259–264. – reference: 40) Maestri A, De Pasquale Ceratti A, Cundari S, et al.: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori, 2005, 91: 135–138. – reference: 16) Notarnicola A, Maccagnano G, Tafuri S, et al.: Comparison of shock wave therapy and nutraceutical composed of Echinacea angustifolia, alpha lipoic acid, conjugated linoleic acid and quercetin (perinerv) in patients with carpal tunnel syndrome. Int J Immunopathol Pharmacol, 2015, 28: 256–262. – reference: 20) Ryan-Harshman M, Aldoori W: Carpal tunnel syndrome and vitamin B6. Can Fam Physician, 2007, 53: 1161–1162. – reference: 35) Peters-Veluthamaningal C, Winters JC, Groenier KH, et al.: Randomised controlled trial of local corticosteroid injections for carpal tunnel syndrome in general practice. BMC Fam Pract, 2010, 11: 54. – reference: 28) Curran MW, Olson J, Morhart M, et al.: Acetyl-L-carnitine (ALCAR) to enhance nerve regeneration in carpal tunnel syndrome: study protocol for a randomized, placebo-controlled trial. Trials, 2016, 17: 200. – reference: 11) Weintraub MI, Cole SP: A randomized controlled trial of the effects of a combination of static and dynamic magnetic fields on carpal tunnel syndrome. Pain Med, 2008, 9: 493–504. – reference: 30) American Association of Electrodiagnostic Medicine, American Academy of Neurology, and American Academy of Physical Medicine and Rehabilitation: Practice parameter for electrodiagnostic studies in carpal tunnel syndrome: summary statement. Muscle Nerve, 2002, 25: 918–922. – reference: 12) Dakowicz A, Kuryliszyn-Moskal A, Kosztyła-Hojna B, et al.: Comparison of the long-term effectiveness of physiotherapy programs with low-level laser therapy and pulsed magnetic field in patients with carpal tunnel syndrome. Adv Med Sci, 2011, 56: 270–274. – reference: 5) Sonohata M, Tsuruta T, Mine H, et al.: Clinical characteristics of neuropathic pain in patients with carpal tunnel syndrome. Hand Surg, 2014, 19: 43–48. – reference: 21) Kulkarni SK, Dhir A: An overview of curcumin in neurological disorders. Indian J Pharm Sci, 2010, 72: 149–154. – reference: 34) Leite JC, Jerosch-Herold C, Song F: A systematic review of the psychometric properties of the Boston Carpal Tunnel Questionnaire. BMC Musculoskelet Disord, 2006, 7: 78. – reference: 15) Weintraub MI, Cole SP: Neuromagnetic treatment of pain in refractory carpal tunnel syndrome: an electrophysiological and placebo analysis. J Back Musculoskeletal Rehabil, 2000, 15: 77–81. – reference: 22) Gorąca A, Huk-Kolega H, Piechota A, et al.: Lipoic acid −biological activity and therapeutic potential. Pharmacol Rep, 2011, 63: 849–858. – reference: 17) Pajardi G, Bortot P, Ponti V, et al.: Clinical usefulness of oral supplementation with alpha-lipoic acid, curcumin phytosome, and B-group vitamins in patients with carpal tunnel syndrome undergoing surgical treatment. Evid Based Complement Alternat Med, 2014, 2014: 891310. – reference: 2) Jablecki CK, Andary MT, So YT, et al. AAEM Quality Assurance Committee: Literature review of the usefulness of nerve conduction studies and electromyography for the evaluation of patients with carpal tunnel syndrome. Muscle Nerve, 1993, 16: 1392–1414. – reference: 8) Chen Y, Zhao CQ, Ye G, et al.: Low-power laser therapy for carpal tunnel syndrome: effective optical power. Neural Regen Res, 2016, 11: 1180–1184. – reference: 39) De Grandis D, Minardi C: Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D, 2002, 3: 223–231. – reference: 42) Musaev AV, Guseinova SG, Imamverdieva SS: The use of pulsed electromagnetic fields with complex modulation in the treatment of patients with diabetic polyneuropathy. Neurosci Behav Physiol, 2003, 33: 745–752. – reference: 41) Colbert AP, Markov MS, Carlson N, et al.: Static magnetic field therapy for carpal tunnel syndrome: a feasibility study. Arch Phys Med Rehabil, 2010, 91: 1098–1104. – reference: 13) Mild KH, Mattsson MO: ELF noise fields: a review. Electromagn Biol Med, 2010, 29: 72–97. – reference: 7) Crow RS: Treatment of the carpal-tunnel syndrome. BMJ, 1960, 1: 1611–1615. – reference: 25) Kapoor S: Curcumin and its emerging role in pain modulation and pain management. Korean J Pain, 2012, 25: 202–203. – reference: 24) Ford I, Cotter M. A, Cameron N. E, et al: The effects of treatment with α-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. 2001, 50: 868–875. – reference: 1) Kuo TT, Lee MR, Liao YY, et al.: Assessment of median nerve mobility by ultrasound dynamic imaging for diagnosing carpal tunnel syndrome. PLoS One, 2016, 11: e0147051. – reference: 31) Schulz KF, Altman DG, Moher D, CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med, 2010, 8: 18. – reference: 18) Kapoor S: Clinical applications of alpha-lipoic acid in the management of neurological disorders besides carpal tunnel syndrome. Eur Rev Med Pharmacol Sci, 2009, 13: 401–402. – reference: 37) Keniston RC, Nathan PA, Leklem JE, et al.: Vitamin B6, vitamin C, and carpal tunnel syndrome. A cross-sectional study of 441 adults. J Occup Environ Med, 1997, 39: 949–959. – reference: 36) Esatbeyoglu T, Huebbe P, Ernst IM, et al.: Curcumin–from molecule to biological function. Angew Chem Int Ed Engl, 2012, 51: 5308–5332. – reference: 27) Ang CD, Alviar MJ, Dans AL, et al.: Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev, 2008, (3): CD004573. – ident: 31 doi: 10.1054/jhsb.2002.0762 – ident: 18 – ident: 39 doi: 10.1016/j.apmr.2010.02.013 – ident: 13 doi: 10.1371/journal.pone.0104973 – ident: 36 doi: 10.1310/CH1N-YBNU-G3CU-JBXR – ident: 4 – ident: 12 doi: 10.3109/15368378.2010.482487 – ident: 2 doi: 10.1002/mus.880161220 – ident: 30 doi: 10.1136/ard.38.6.560 – ident: 11 doi: 10.1111/j.1526-4637.2007.00324.x – ident: 3 doi: 10.1016/j.berh.2015.04.026 – ident: 26 doi: 10.1186/s13063-016-1324-2 – ident: 29 doi: 10.1186/1741-7015-8-18 – ident: 34 doi: 10.1002/anie.201107724 – start-page: S0213 issn: 0213-4853 year: 2016 ident: 10 publication-title: Neurologia – ident: 37 doi: 10.2165/00126839-200203040-00001 – volume: 6 start-page: e012053 issn: 2044-6055 year: 2016 ident: 6 publication-title: BMJ Open doi: 10.1136/bmjopen-2016-012053 – ident: 15 doi: 10.1177/0394632015584501 – ident: 38 doi: 10.1177/030089160509100206 – ident: 17 – ident: 32 doi: 10.1186/1471-2474-7-78 – ident: 41 doi: 10.1177/197140090702000612 – ident: 21 doi: 10.1523/JNEUROSCI.5803-08.2009 – ident: 23 doi: 10.3344/kjp.2012.25.3.202 – ident: 9 doi: 10.4103/2277-9175.186983 – ident: 24 doi: 10.3390/molecules16064567 – ident: 19 – ident: 28 doi: 10.1002/mus.10185 – ident: 14 doi: 10.3233/BMR-2000-152-305 – ident: 35 doi: 10.1097/00043764-199710000-00007 – ident: 40 doi: 10.1023/A:1025184912494 – ident: 20 doi: 10.4103/0250-474X.65012 – ident: 5 doi: 10.1142/S0218810414500087 – ident: 8 doi: 10.4103/1673-5374.187063 – ident: 1 doi: 10.1371/journal.pone.0147051 – ident: 25 doi: 10.1002/14651858.CD004573.pub3 – ident: 16 doi: 10.1155/2014/891310 – ident: 22 doi: 10.1053/meta.2001.24914 – volume: 43 start-page: 2406 issn: 0028-3878 year: 1993 ident: 27 publication-title: Neurology doi: 10.1212/WNL.43.11.2406 – ident: 7 doi: 10.1136/bmj.1.5186.1611 – ident: 33 doi: 10.1186/1471-2296-11-54 – reference: 27079660 - Trials. 2016 Apr 14;17:200 – reference: 18646107 - Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004573 – reference: 22787555 - Korean J Pain. 2012 Jul;25(3):202-3 – reference: 18777606 - Pain Med. 2008 Jul-Aug;9(5):493-504 – reference: 19961049 - Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):401-2 – reference: 14635988 - Neurosci Behav Physiol. 2003 Oct;33(8):745-52 – reference: 24300003 - Neuroradiol J. 2007 Dec 31;20(6):676-93 – reference: 22037175 - Adv Med Sci. 2011;56(2):270-4 – reference: 26612240 - Best Pract Res Clin Rheumatol. 2015 Jun;29(3):440-53 – reference: 20599049 - Arch Phys Med Rehabil. 2010 Jul;91(7):1098-104 – reference: 26764488 - PLoS One. 2016 Jan 14;11(1):e0147051 – reference: 17872812 - Can Fam Physician. 2007 Jul;53(7):1161-2 – reference: 12074615 - J Hand Surg Br. 2002 Jun;27(3):259-64 – reference: 24641740 - Hand Surg. 2014;19(1):43-8 – reference: 11474472 - Metabolism. 2001 Aug;50(8):868-75 – reference: 17054773 - BMC Musculoskelet Disord. 2006 Oct 20;7:78 – reference: 12115985 - Muscle Nerve. 2002 Jun;25(6):918-22 – reference: 20838516 - Indian J Pharm Sci. 2010 Mar;72(2):149-54 – reference: 15948540 - Tumori. 2005 Mar-Apr;91(2):135-8 – reference: 22566109 - Angew Chem Int Ed Engl. 2012 May 29;51(22):5308-32 – reference: 22001972 - Pharmacol Rep. 2011;63(4):849-58 – reference: 19641113 - J Neurosci. 2009 Jul 29;29(30):9500-9 – reference: 20670438 - BMC Fam Pract. 2010 Jul 29;11:54 – reference: 317239 - Ann Rheum Dis. 1979 Dec;38(6):560 – reference: 27563630 - Adv Biomed Res. 2016 Jul 29;5:120 – reference: 25127118 - PLoS One. 2014 Aug 15;9(8):e104973 – reference: 13813041 - Br Med J. 1960 May 28;1(5186):1611-5 – reference: 8232968 - Neurology. 1993 Nov;43(11):2406-9 – reference: 8232399 - Muscle Nerve. 1993 Dec;16(12):1392-414 – reference: 12455197 - Drugs R D. 2002;3(4):223-31 – reference: 21642934 - Molecules. 2011 Jun 03;16(6):4567-98 – reference: 25630774 - Neurosciences (Riyadh). 2015 Jan;20(1):4-9 – reference: 20707642 - Electromagn Biol Med. 2010 Aug;29(3):72-97 – reference: 27638495 - BMJ Open. 2016 Sep 16;6(9):e012053 – reference: 9343760 - J Occup Environ Med. 1997 Oct;39(10):949-59 – reference: 20334633 - BMC Med. 2010 Mar 24;8:18 – reference: 22388446 - J Back Musculoskelet Rehabil. 2000 Jan 1;15(2):77-81 – reference: 25953494 - Int J Immunopathol Pharmacol. 2015 Jun;28(2):256-62 – reference: 16566084 - HIV Clin Trials. 2005 Nov-Dec;6(6):344-50 – reference: 19499849 - Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):133-9 – reference: 24563654 - Evid Based Complement Alternat Med. 2014;2014:891310 – reference: 27630706 - Neural Regen Res. 2016 Jul;11(7):1180-4 |
| SSID | ssj0027048 |
| Score | 2.0596232 |
| Snippet | [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa®) combined with extremely-low-frequency... [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa ) combined with extremely-low-frequency... [Purpose] The aim of this study was to investigate the clinical effects of a nutraceutical composed (Xinepa ® ) combined with extremely-low-frequency... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 777 |
| SubjectTerms | Carpal tunnel syndrome Dietary supplements Electromagnetism Functional foods & nutraceuticals Magnetic fields Nutraceuticals Original |
| Title | Efficacy of dietary supplement with nutraceutical composed combined with extremely-low-frequency electromagnetic fields in carpal tunnel syndrome |
| URI | https://www.jstage.jst.go.jp/article/jpts/30/6/30_jpts-2018-013/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/29950763 https://www.proquest.com/docview/2232603503 https://www.proquest.com/docview/2061405471 https://pubmed.ncbi.nlm.nih.gov/PMC6016299 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Physical Therapy Science, 2018, Vol.30(6), pp.777-784 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9RADLb64MAFKJQSKNUg9YSUbbLzSPaAUIX6UKUiDl1pb9FMZtJutSRlkxXkZ_CPsfOCrfbAJUoUTyaJ7fiz47EBjs2YyzDW1pcWJVikY-ujGTI-ggklXBCmoaEFztdf1eVUXM3kbAv6ZpzdCyw3unbUT2q6XIx-_ag_o8J_arr3xJOT-4eqHPFgFEXRNuyiSVLkhV2L-K_nFTRttNA2SvS84qhbqPdo8JppenKP6OzWbQKej_Mn_zFI5y_gWYck2WnL-j3YcvlLeP6te-_spi0X8Ap-n1GVCJ3WrMiYnbtKL2tWUjPPJjLIKBLL8hVO0Ue2GeWZF6WztIOeM-40RPgdp2jiovYXxU8_W7ZZ2DXrWul817c5LYlkTVZcyeY5o787eL1qRdk0rK-OsA_T87ObL5d-14jBT6kclp9ZVFwZaSMm6IiLiZDCGVRcboVx3ATWSctjLVOrxk4Yi25RNjY2lDoOqcMVfw07eZG7N8BMFjkpZaZE6oTKtDbOchdaza0KuBEefOx5kKRdlXJqlrFIyFtBhiXEsIQHCTLMg-OB-KEtzrGZ7LRl5kDUaeVApGjTHCAeihOExQMJLX7DL4gHh70cJL2QJgit0B3kMuAefBhOo37STxedu2JFF0QAhLg4Cj04aMVmuA2EAgjHFY6O1gRqIKDa3-tn8vldUwOcqujg8Lf_Me87eEpP1caNDmGnWq7ce0RSlTmC7YtZeNToyh9YEycf |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+dietary+supplement+with+nutraceutical+composed+combined+with+extremely-low-frequency+electromagnetic+fields+in+carpal+tunnel+syndrome&rft.jtitle=Journal+of+physical+therapy+science&rft.au=Paolucci%2C+Teresa&rft.au=Piccinini%2C+Giulia&rft.au=Nusca%2C+Sveva+Maria&rft.au=Marsilli%2C+Gabriella&rft.date=2018-01-01&rft.issn=0915-5287&rft.volume=30&rft.issue=6&rft.spage=777&rft_id=info:doi/10.1589%2Fjpts.30.777&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0915-5287&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0915-5287&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0915-5287&client=summon |